Prostate biopsies and effects on erectile function post-biopsy

There have long been suggestions that having a prostate biopsy could be associated with at least a temporary decline in erectile function. A new study in BJU International has now shed more light on this matter. … READ MORE …

Risk for prostate cancer among black males in England

A newly published article in the British Medical Journal has shown that black males in England are twice as likely to be diagnosed with prostate cancer as white males, and are twice as likely to die of prostate cancer too. … READ MORE …

How many “different” types of prostate cancer are there?

This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …

Important new standards for data collection in studies of advanced prostate cancer

Recently we noted that Morgans et al. had published information about a proposed, standardized set of patient-centered outcomes data for advanced prostate cancer that would facilitate cross-comparison of data from the many trials that take now place in the management of TxNxM+ prostate cancer. … READ MORE …

Management of incident prostate cancer on active surveillance

Back in the dim and distant past (i.e., the 1980s and the very early 1990s, before PSA testing was widespread) one of the most common ways to find early stage prostate cancer was as an incidental consequence of the conduct of a transurethral resection of the prostate (a “TURP”) to treat symptoms of urinary tract obstruction. … READ MORE …

INO-5150 enters initial clinical trials

Inovio Pharmaceuticals is initiating a Phase I trial of INO-5150 — a new type of immunotherapy for prostate cancer which targets both the prostate-specific antigen (PSA) and the and the prostate specific membrane antigen (PSMA). … READ MORE …

Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers